Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 medication-friendly options.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.